[Is antiviral therapy indicated in patients with rheumatological diseases?].
There is recently being observed increase of the specific weight of the opportunistic bacterial-and-viral infections, the initial onset or reactivation of which are associated with the immunity suppression, e.g. due to immunosuppressive therapy. Viral infection in cases with rheumatic diseases often leads to severe process of the main disease and development of serious complications, such as hepatitis, nephritis, pneumonia and others. This is especially actual at the early stages of the disease in cases with viral infection in the anamnesis, since in such cases it activates the main disease, that of course raises the question of the use of antiviral agents in the complex therapy.
Egorova
O N
ON
Balabanova
R M
RM
D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D005455:Fluorescent Antibody Technique; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D018259:Herpesvirus 1, Human / Q000276:immunology; D018258:Herpesvirus 2, Human / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D012216:Rheumatic Diseases / Q000150:complications* / Q000473:pathology; D055502:Secondary Prevention; D016036:Seroepidemiologic Studies; D016896:Treatment Outcome
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007074:Immunoglobulin G